Aprocitentan - Idorsia Pharmaceuticals

Drug Profile

Aprocitentan - Idorsia Pharmaceuticals

Alternative Names: AC 080; ACT-132577

Latest Information Update: 08 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Actelion Pharmaceuticals
  • Developer Idorsia Pharmaceuticals
  • Class Antihypertensives; Small molecules
  • Mechanism of Action Endothelin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hypertension
  • Phase I Cardiovascular disorders

Most Recent Events

  • 14 Aug 2017 Actelion plans a phase I trial in Healthy volunteers (NCT03245229)
  • 10 Aug 2017 Phase-I clinical trials in Cardiovascular disorders (In volunteers) in Czech Republic (PO) (NCT03245229)
  • 16 Jun 2017 Actelion Pharmaceuticals has been acquired by Janssen Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top